anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Single-pollutant models have linked prenatal PM2.5 exposure to lower birthweight. However, analyzing air pollutant mixtures better captures pollutant interactions and total effects. Unfortunately, strong correlations between pollutants restrict traditional methods.
OBJECTIVES: We explored the association between exposure to a mixture of air pollutants during different gestational age windows of pregnancy and birthweight.
METHODS: We included 4,635 mother-infant dyads from a New York State birth cohort born 2008-2010. Air pollution data were sourced from the EPA's Community Multiscale Air Quality model and matched to the census tract centroid of each maternal home address. Birthweight and gestational age were extracted from vital records. We applied linear regression to study the association between prenatal exposure to PM2.5, PM10, NOX, SO2, and CO and birthweight during six sensitive windows. We then utilized Bayesian kernel machine regression to examine the non-linear effects and interactions within this five-pollutant mixture. Final models adjusted for maternal socio-demographics, infant characteristics, and seasonality.
RESULTS: Single-pollutant linear regression models indicated that most pollutants were associated with a decrement in birthweight, specifically during the two-week window before birth. An interquartile range increase in PM2.5 exposure (IQR: 3.3 µg/m3) from the median during this window correlated with a 34 g decrement in birthweight (95 % CI: -54, -14), followed by SO2 (IQR: 2.0 ppb; β: -31), PM10 (IQR: 4.6 µg/m3; β: -29), CO (IQR: 60.8 ppb; β: -27), and NOX (IQR: 7.9 ppb; β: -26). Multi-pollutant BKMR models revealed that PM2.5, NOX, and CO exposure were negatively and non-linearly linked with birthweight. As the five-pollutant mixture increased, birthweight decreased until the median level of exposure.
DISCUSSION: Prenatal exposure to air pollutants, notably PM2.5, during the final two weeks of pregnancy may negatively impact birthweight. The non-linear relationships between air pollution and birthweight highlight the importance of studying pollutant mixtures and their interactions.
Patients received p-ATG for 5 consecutive days (day 1-5), at a dose of 20 mg/kg/day. CSA is started at 3 mg/kg orally in two doses. Concentrations maintained at 200-250 ng/ml to achieve maximum efficacy and then tapered by 25 mg every 3 months; Avatrombopag: 40 mg orally once daily for a total of 12 weeks. A total of 39 patients were expected to be included.
PROBLEM TO BE SOLVED: To obtain the subject composition suppressing adsorption and penetration of a perfume and continuing a refreshing feeling by blending a large amount of ethanol with citral and menthol in a specific ratio and packing the blend into a container made of a specific synthetic resin. SOLUTION: This composition is obtained by blending >=20% of ethanol with citral and menthol in the weight ratio of 2:1 to 1:50 (especially 1:1 to 1:10) and is packed into a container made of a synthetic resin having the ratio (cm<2> /ml) of the inner area of the container in contact with the composition to the composition volume of >=2, especially 4-5. A container made of a polyethylene terephthalate is preferable as the container. The amount of menthol blended is preferably 0.01-2.0wt.% and that of citral is preferably 0.001-1.0%. The composition to be packed is preferably a liquid or in a liquid state. The composition is preferably mixed with a polyoxyethylene hardened castor oil having 40-100 addition mols of ethylene oxide.
No drug-drug interaction studies have been performed with Amitiza. in vivo

Based upon the results of human microsome studies, there is low likelihood of pharmacokinetic drug-drug interactions. studies using human liver microsomes indicate that cytochrome P450 isoenzymes are not involved in the metabolism of lubiprostone. Further studies indicate microsomal carbonyl reductase may be involved in the extensive biotransformation of lubiprostone to the metabolite M3 [see ]. Additionally, studies in human liver microsomes demonstrate that lubiprostone does not inhibit cytochrome P450 isoforms 3A4, 2D6, 1A2, 2A6, 2B6, 2C9, 2C19, or 2E1, and studies of primary cultures of human hepatocytes show no induction of cytochrome P450 isoforms 1A2, 2B6, 2C9, and 3A4 by lubiprostone. Based on the available information, no protein binding–mediated drug interactions of clinical significance are anticipated. in vitroIn vitroin vitroClinical Pharmacology (12.3)in vitroin vitro

Interaction potential with diphenylheptane opioids (e.g. methadone): Non-clinical studies have shown opioids of the diphenylheptane chemical class (e.g., methadone) to dose-dependently reduce the activation of ClC-2 by lubiprostone in the gastrointestinal tract. There is a possibility of a dose-dependent decrease in the efficacy of Amitiza in patients using diphenylheptane opioids.
Methods and systems provide secure data transmission from a mobile device to a central computer system over a communication network. The method includes executing a first computer program in the mobile device and allocating by the first computer program a volatile memory space in the mobile device for a defined session. The method includes storing data in the allocated volatile memory space. The method includes transmitting the stored data to the central computer using a secure transmission protocol over the communication network. The method includes de-allocating by the first computer program the volatile memory space at the termination of the session. The de-allocation erases the transmitted data from the volatile memory space.
Mulligan Mobilization was administered 9 sessions (3 days a week, for 3 weeks). .
Electrically evoked frequency-following responses (eFFRs) provide insight in the phase-locking ability of brainstem of cochlear-implant (CI) users. eFFRs can potentially be used to gain insight in the individual differences in the biological limitation on temporal encoding of the electrically stimulated auditory pathway, which can be inherent to the electrical stimulation itself and/or the degenerative processes associated with hearing loss. One of the major challenge of measuring eFFRs in CI users is the process of isolating the stimulation artifact from the neural response, as both the response and the artifact overlap in time and have similar frequency characteristics. Here we introduce a new artifact removal method based on template subtraction that successfully removes the stimulation artifacts from the recordings when CI users are stimulated with pulse trains from 128 to 300 pulses per second in a monopolar configuration. Our results show that, although artifact removal was successful in all CI users, the phase-locking ability of the brainstem to the different pulse rates, as assessed with the eFFR differed substantially across participants. These results show that the eFFR can be measured, free from artifacts, in CI users and that they can be used to gain insight in individual differences in temporal processing of the electrically stimulated auditory pathway.
Multi-component packaging unit (kit-of-parts) comprises at least two separately assembled containers. A first container contains at least one oxidizing preparation comprising at least one hydrogen peroxide as an oxidizing agent in a liquid cosmetic carrier and at least one ethoxylated fatty alcohol having 10-30 ethylene oxide units as a nonionic surfactant. A second container contains at least one bleaching powder containing at least one persulfate salt as a bleach enhancer, and additionally an optionally hydrated silicon dioxide compound. Multi-component packaging unit (kit-of-parts) comprises at least two separately assembled containers. A first container contains at least one oxidizing preparation (a) comprising at least one hydrogen peroxide as an oxidizing agent in a liquid cosmetic carrier and at least one ethoxylated fatty alcohol having 10-30 ethylene oxide units as a nonionic surfactant. A second container contains at least one bleaching powder (b) containing at least one persulfate salt as a bleach booster, which is composed of potassium peroxodisulfate, sodium peroxodisulfate and ammonium peroxodisulfate, and additionally an optionally hydrated silicon dioxide compound. The oxidizing preparation of the first container or a third separately assembled container additionally comprises at least one carboxylic acid ester oil having a total content of 12-80 carbon atoms, which is formed from (i) monoesters of one equivalent of carboxylic acid and alkanol, (ii) diesters from two equivalents of carboxylic acid and one equivalent of alkane diol, (iii) diesters from one equivalent dicarboxylic acid and two equivalents of alkanol, and (iv) triesters of three equivalents of carboxylic acid and one equivalent of glycerin. An independent claim is also included for a ready-to-use agent for bleaching of human hair, comprising the components of a multi-component packaging unit, which is prepared by mixing the individual preparations instantly before applying on the hair.
Aggregated species of amyloid-β (Aβ) are one of the pathological hallmarks in Alzheimer's disease (AD), and ligands that selectively target different Aβ deposits are of great interest. In this study, fluorescent thiophene-based ligands have been used to illustrate the features of different types of Aβ deposits found in AD brain tissue. A dual-staining protocol based on two ligands, HS-276 and LL-1, with different photophysical and binding properties, was developed and applied on brain tissue sections from patients affected by sporadic AD or familial AD associated with the PSEN1 A431E mutation. When binding to Aβ deposits, the ligands could easily be distinguished for their different fluorescence, and distinct staining patterns were revealed for these two types of AD. In sporadic AD, HS-276 consistently labeled all immunopositive Aβ plaques, whereas LL-1 mainly stained cored and neuritic Aβ deposits. In the PSEN1 A431E cases, each ligand was binding to specific types of Aβ plaques. The ligand-labeled Aβ deposits were localized in distinct cortical layers, and a laminar staining pattern could be seen. Biochemical characterization of the Aβ aggregates in the individual layers also showed that the variation of ligand binding properties was associated with certain Aβ peptide signatures. For the PSEN1 A431E cases, it was concluded that LL-1 was binding to cotton wool plaques, whereas HS-276 mainly stained diffuse Aβ deposits. Overall, our findings showed that a combination of ligands was essential to identify distinct aggregated Aβ species associated with different forms of AD.
A water-soluble choline phosphoric acid diglyceride ester compound is obtained by reacting a natural choline phosphoric acid diglyceride ester, free from colamine phosphoric acid diglyceride ester and having a moderately preponderant proportion of essential and other unsaturated fatty acids in relation to the total fatty acid content, with an aqueous solution of sodium desoxycholate in an alkaline medium and in the presence of an inert gas, e.g. nitrogen, less than 1 mole but not less than 0.8 mole of sodium desoxycholate being used for 1 mole of the diglyceride ester.  The pH value of the reaction mixture is preferably above 8.  The diglyceride ester may be obtained from soya bean crude lecithian by the procedure described in Specification 877,031 and may comprise in relation to the total fatty acid content more than 80% of unsaturated fatty acids of which the greatest part consists of essential fatty acids, e.g. linoleic and linolenic acids. Up to 50% by weight of the diglyceride ester fraction may be replaced by lysolecithins which may also be obtained by the process disclosed in Specification 877,031 and contains about 28% of essential fatty acids in relation to the total fatty acids. In a modification of the process a very dilute alcoholic solution containing about 1% of diglyceride esters such as is described in the example of Specification 877,031 is treated with a small amount (e.g. 0.2% per gram of choline phosphoric acid diglyceride ester) of alpha-tocophenol (preferably in the form of its acetate) to form an adduct therewith, the alcohol distilled off under reduced pressure in the presence of an inert gas such as nitrogen or carbon dioxide and the adduct then reacted in alkaline medium with an aqueous solution of sodium desoxycholate in an amount of less than 1 mole but not less than 0.8 mole per mole of the diglyceride ester.  Up to 2% by weight of the alpha-tocophenol may be added to the diglyceride esters or to the mixture of diglyceride esters and lysolecithin.  The products have therapeutic value, e.g. in the treatment of arterioscherosio and diabetes and may be used in the form of a 5 or 10% aqueous solution which is applied parenterally, e.g. intravenously.
An example system includes a microfluidic cavity; a retaining feature within the microfluidic cavity, and a releasing feature. The retaining feature is to position capsules at a predetermined location in the microfluidic cavity. The capsules have a thermally degradable shell enclosing a material therein. The releasing feature is to selectively cause degradation of the shell to release the material into the microfluidic opening. The releasing feature is to generate heat to facilitate degradation of the shell. In some examples, the retaining feature is a physical barrier sized to prevent flow of the capsule and to allow flow of the released materials through the microfluidic cavity.
Vernal keratoconjunctivitis (VKC) is a chronic allergic disease, characterised by ocular surface inflammation lasting all year with seasonal relapses. Active phases of VKC are characterised by intense ocular symptoms and require treatment with topical steroids to control inflammation and corneal damage. To date, safe and effective therapies in preventing relapses of VKC are not available. Recently, the use of oral administration of probiotics for allergic diseases have been proposed. No data are available on the effects of probiotics on ocular allergies. This multicenter, double-masked, randomised, controlled clinical trial will allow to obtain more data on the efficacy of oral treatment with Lactobacillus Rhamnosus GG in patients affected by VKC. Patients with VKC will be treated with Lactobacillus Rhamnosus GG or placebo in addition to ketotifen fumarate 0.025% eye drops (standard treatment). The number of relapses per year, signs and symptoms of the disease, total symptom score (TSyS), total sign score (TSS), biochemical and molecular parameters will be evaluated at different time points.
<P>PROBLEM TO BE SOLVED: To provide a bleaching agent having high bleaching effect, little adverse effect and high safety.  <P>SOLUTION: The bleaching agent comprises a mercaptosulfonic acid compound or its salt as an active ingredient. The mercaptosulfonic acid compound may be a mercaptoalkane sulfonic acid or its dimer and a salt of the mercaptosulfonic acid compound may be a metallic salt (e.g. mesna or dimesna) thereof. The content of the mercaptosulfonic acid compound or its salt may be about 0.01-50 wt.% expressed in terms of solid content based on total of bleaching agent. The bleaching agent can suppress melanogenesis. The bleaching agent can be used in a form of an oral agent or an external preparation.  <P>COPYRIGHT: (C)2007,JPO&INPIT
OBJECTIVE: To examine the functional mobility and lumbopelvic rhythm of the continent and incontinent women.
DESIGN: An observational pilot study was performed with two groups of women, who never experienced falls.
METHODS: Participants were 27 women with urinary incontinence and 27 matched controls. The incontinent group had urinary incontinence assessed by the International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) (score ≥1); and the continent group had an ICIQ-SF score equal to 0. The functional mobility and lumbopelvic rhythm were assessed using G-Sensor® gadget wireless system. With the G-sensor® at the second lumbar vertebra, the participants performed the Walk-Test (functional mobility), Time Up and Go (TUG) (functional mobility), and lumbopelvic rhythm. Student T test, Chi-Square, and Mann-Whitney test were applied to compare continuous variables between groups. p < 0.05 for significance level. Hegdes'g statistic and R2 [Z2/(total n)] were used to effect size.
RESULTS: Walk-test was not different between groups. TUG was different between groups: the continent group (11.0 ± 2.1s) was faster than the incontinent group (12.5 ± 3.3s) (p = 0.03). The sitting-to-standing position knee flexion angle was larger in the continent group (45.0 ± 17.2°) than in the incontinent (34.1 ± 18.8°) (p = 0.03).
CONCLUSION: The incontinent group showed a decrease in functional mobility according to the TUG test. Limiar differences in the flexion angle from sitting to standing suggest incontinent women might have a lower potential for hip flexor moment during hip lifting.
BACKGROUND: As total joint arthroplasty (TJA) moves to the outpatient setting, it is becoming clear that postoperative urinary retention (POUR) is a potential impediment to same-day discharge. Although risk factors for POUR have been widely studied, the lack of their clinical utility warrants investigation of specific preoperative factors that can assist in surgical planning and patient optimization. The purpose of the current study was to determine whether preoperative symptom surveys and bladder scanning are useful tools in identifying POUR risk.
METHODS: We performed a prospective analysis of patients undergoing total hip arthroplasty (THA) and total knee arthroplasty (TKA) at a high-volume orthopaedic hospital between December 1, 2020, and September 30, 2021. A total of 507 patients (324 female and 183 male) undergoing TJA completed the American Urological Association (AUA) symptom index preoperatively and then again at 14 and 64 days postoperatively. Post-void bladder scans were obtained in the immediate preoperative setting. POUR was defined as a bladder volume of >500 mL that required catheterization. Chi-square and quintile analysis were used to compare bladder scanning volumes, and Student t tests were used to compare AUA scores.
RESULTS: The rate of POUR was 37% (66 female and 34 male) and 23% (37 female and 19 male) in the TKA and THA groups, respectively. Increasing post-void residual volume (PVRV) measured on preoperative bladder scanning was found to be predictive of POUR. Among the TKA cohort, younger age and lower body mass index were also associated with increased catheterization, although age was not statistically significant. The AUA symptom survey was not found to correlate with POUR in either population.
CONCLUSIONS: There was a predictable and exponential increase in the rate of catheterization as preoperative PVRV increased from 50 to 200 mL. The AUA symptom score showed no utility in predicting POUR in our study population. We propose that preoperative bladder ultrasonography become standard practice in TJA, especially among patients scheduled for same-day discharge.
LEVEL OF EVIDENCE: Prognostic Level II . See Instructions for Authors for a complete description of levels of evidence.
Chronic inflammatory skin diseases, despite low mortality, significantly impair quality of life. Up to 80% of dermatological patients experience severe itch and poor sleep, and related such mental health challenges as anxiety and depression. The relationship between skin diseases and mental health highlights the challenges that doctors face in treating these conditions. Existing psychotherapeutics such as Mindfulness training, Cognitive Behavioural Therapy, and Acceptance and Commitment Therapy are widely used and effective in the treatment of mental health illness. However, there is limited evidence on the application of such interventions in dermatology and most mental health apps lack robust clinical evaluation. We report the design of a randomised controlled trial to evaluate the efficacy and implementation of a mobile app containing dermatology-specified psychotherapeutic strategies in reducing QoL burden.
Dose escalated by cohorts Hydroxychloroquine 200-600 mg pill every other day. Bortezomib 1.0-1.3mg/m2 IV, days 1, 4, 8, and 11 of each 21 day cycle.
Psoriasis, characterized by aberrant epidermal keratinocyte proliferation and differentiation, is a chronic inflammatory immune-related skin disease. Diosmetin (Dios), derived from citrus fruits, exhibits anti-inflammatory and anti-proliferative properties. In this study, IL-17A-induced HaCaT cell model and Imiquimod (IMQ)-induced mouse model were utilized to investigate the effects of Dios against psoriasis. The morphology and biomarkers of psoriasis were regarded as the preliminary evaluation including PASI score, skin thickness, H&E staining, EdU staining and inflammatory factors. Transcriptomics analysis revealed PGC-1α as a key target for Dios in ameliorating psoriasis. Specifically, Dios, through PGC-1α, suppressed YAP-mediated proliferation and inflammatory responses in psoriatic keratinocytes. In conclusion, Dios shows promise in psoriasis treatment and holds potential for development as targeted medications for application in psoriasis.
The present invention discloses a kind of sore-throat relieving Chinese medicine composition containing Herba Androsaces Umbellatae (Herba Androsaces Coccineae), uses foxtail millet seed, Herba Androsaces Umbellatae (Herba Androsaces Coccineae), Radix Ophiopogonis, Ampelopsis cantoniensis （Hook. et Arn.） Planch. var. grossedentata Hand.-Mazz., Folium et Cacumen Artemisiae Halodendri seed powder and EM original solution etc. to be prepared from.Coarse grain foxtail millet seed strengthening the spleen and nourishing the stomach, hankers quenching one's thirst, and QI invigorating invigorating middle warmer is suitable for the dysphoria with smothery sensation of the patient of throat disease thirsty.Herba Androsaces Umbellatae (Herba Androsaces Coccineae) heat-clearing and toxic substances removing, reducing swelling and alleviating pain is kind controls laryngopharyngeal diseases, and Radix Ophiopogonis, nourishing YIN and moistening the lung, promoted the production of body fluid, and Ampelopsis cantoniensis （Hook. et Arn.） Planch. var. grossedentata Hand.-Mazz. heat-clearing and toxic substances removing is inducing diuresis and reducing edema, all medicine compatibilities clear tonification gas, heat-clearing and toxic substances removing inducing diuresis to remove edema, strengthening vital QI to eliminate pathogenic factors ground preventing and treating laryngopharyngeal diseases.A kind of sore-throat relieving Chinese medicine composition containing Herba Androsaces Umbellatae (Herba Androsaces Coccineae), micro-hardship is micro-sweet, can buccal, directly contact lesions position, curative effect is the most excellent rapidly, easy to use, it is simple to carry.The outer used time also can apply ointment or plaster skin sore, furuncle furuncle carbuncle etc..
In the investigators previous evaluation of Complicated Grief Group Therapy (CGGT) in bereaved dementia caregivers (2014-NIRG-305569), CGGT was administered to participants in a prospective, randomized-controlled trial. Participants in 5 treatment groups confirmed clinically significant reduction in complicated grief on the Inventory of Complicated Grief. In that study, intervention elements suitable for adaption in a preventative care approach were identified. The investigators are adapting these elements of CGGT for soon-to-be bereaved dementia caregivers at risk for complicated grief-Pre-Loss Group Therapy (PLGT) to facilitate healthy death preparedness and eventual bereavement.

Specific Aims: 1) Assess preparedness for death and grief of bereaved and soon-to-be bereaved caregivers. 2) Adapt CGGT treatment elements into a manualized pre-loss preparedness group psychotherapy-(PLGT)-for dementia caregivers at risk for complicated grief. 3) Implement and evaluate three PLGT cohorts (NTotal = 40) in three long-term care facilities with family caregivers at-risk for complicated grief whose care recipient has a life expectancy of 6 months or less and resides in a long-term care facility.